STAT3 and neoplasm: Other JAK and Src inhibitors such as AZD1480, WP-1066, desatinib, and saracatinib demonstrate the reduction of STAT3 phosphorylation as well as downstream implications like increased apoptosis and decreased tumor growth [68–71].